Quidel said this week that increased flu testing and subsequent demand for its respiratory diagnostic tests — including its relatively new Quidel Molecular portfolio — helped drive a 63 percent year-over-year spike in first-quarter revenues.

In addition, Quidel President and CEO Doug Bryant said that the company expected two programs — the company's AmpliVue isothermal amplification-based molecular diagnostic products and Sofia fluorescent immunoassay products — to be most responsible for near-term growth at the firm.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.